-- CORAL-CEPI: Primary series samRNA vaccination elicits strong neutralizing antibody (nAb) responses that persist for at least 6 months, including…
PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences’ comprehensive data…
NKGen Biotech, Inc. (“NKGen”), a clinical stage Natural Killer (NK) cell therapy company, has entered into a merger agreement with…
PALO ALTO, Calif., April 14, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a subsidiary of Sorrento Therapeutics, Inc.…
For the nine months ended February 28, 2023 vs. the same period in 2022, revenues, excluding sales of Covid-related products,…
New research demonstrates the value of genomic and epigenomic methylation sequencing capabilities of Predicine liquid biopsy platform for biomarker discovery,…
CHASKA, Minn., April 14, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that it received…
MOORESVILLE, N.C., April 14, 2023 (GLOBE NEWSWIRE) -- The Hemp Doctor, a leading provider of high-quality innovative products, is proud…
First clinical results to be presented at the AACR Annual Meeting 2023 showed 23ME-00610 demonstrated an acceptable safety and tolerability…
JENA, Germany, April 14, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory…